X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
EMR: A step towards patents - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jun 6, 2003

    EMR: A step towards patents

    The Indian pharmaceutical industry is significantly influenced by price controls and the patent regime. The National Pharmaceutical Pricing Authority (NPPA) in accordance with the Drug Price Control Order (DPCO) controls prices of many pharmaceutical drugs. The Indian Patents Act, 1970, on the other hand, provides for process patents. Come 2005 and India will have to allow product patents, as it is a signatory to WTO guidelines dealing with the protection of intellectual property.

    As a step in this direction, the Indian government recently passed The Patents (Second Amendment) Amendment Bill, 1999. This bill though provided for acceptance of product patents, the same would be processed only after 1st January 2005, since India has a ten-year transition period for the introduction of product patents. Until then, Exclusive Marketing Rights (EMR) would be granted to such products. In this context, let us examine the various regulatory provisions relating to EMR.

    EMR gives the holder exclusive rights to sell or distribute the drug or medicine for a period of five years or till the grant of patent or the date of rejection of application for the grant of patent, whichever is earlier. EMR thus provides a legal safeguard from generics to the company introducing a product in the market.

    EMR can be granted to an applicant if he has already filed an application for the product patent after 1st January 1995 in any of the convention countries (i.e. a country with which India has a reciprocal agreement for dealing in patent applications). EMR can also be granted if the applicant has made an application in India for a process patent of the drug after 1st January 1995. Moreover, even if the applicant has obtained a marketing approval for the drug and the drug controller has not rejected his patent application, EMR application can be granted.

    However, if two years after the grant of EMR, anyone challenges and proves that the product for which EMR has been obtained has failed to fulfill its social duties or is not being reasonably priced, the drug controller may order the transfer of EMR license to the challenger. The drug controller can also revoke the EMR in public interest.

    There is an apprehension in the industry that with the introduction of EMR, many readily available drugs will come under the purview of EMR and consequently their prices will increase. However, this is not correct. EMR is granted only for those drugs for which patent application has been filed after 1st January 1995. Moreover, it takes atleast 8 – 10 years for the drug to reach the market after it is patented. Hence, at the earliest, EMR applications will only be filed during the period 2003 – 2004. Therefore, not many drugs are likely to be introduced through the EMR route.

    Yet, EMR is a step forward in India’s obligation of complying with the WTO regulation of providing product patents by 1st January 2005. It has demonstrated India’s commitment in fulfilling its duty towards WTO regulations. However, the amended Act has still fallen short of providing product patent and hence another amendment to The Patents Act will have to be made for the introduction of the product patent regime.

     

     

    Equitymaster requests your view! Post a comment on "EMR: A step towards patents". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 17, 2017 03:37 PM

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS